Dr. Shain on Subcutaneous Therapy for Patients With Multiple Myeloma

Kenneth H. Shain, MD, PhD
Published: Tuesday, Aug 08, 2017



Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses the impact of subcutaneous therapy, such as bortezomib (Velcade) and daratumumab (Darzalex) for patients with multiple myeloma.

For certain drugs, subcutaneous use of therapy will be important for the field of myeloma, Shain explains. It has changed how physicians take care of patients in helping to mitigate some toxicities, as seen with subcutaneous treatment with bortezomib.

The implementation of this is something that’s going to take time, he says, as it is more of a delivery change versus a mitigation of toxicity change.


Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses the impact of subcutaneous therapy, such as bortezomib (Velcade) and daratumumab (Darzalex) for patients with multiple myeloma.

For certain drugs, subcutaneous use of therapy will be important for the field of myeloma, Shain explains. It has changed how physicians take care of patients in helping to mitigate some toxicities, as seen with subcutaneous treatment with bortezomib.

The implementation of this is something that’s going to take time, he says, as it is more of a delivery change versus a mitigation of toxicity change.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x